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Abstract: Introduction of antiplatelet agents has contributed substantially to improve the 
outcome of patients with acute coronary syndromes. Meta-analysis of the studies on abciximab 
administration during primary percutaneous coronary intervention (PCI) for acute ST-segment 
elevation myocardial infarction (STEMI) has clearly confirmed the mortality benefit associated 
with intravenous bolus and infusion of abciximab compared to placebo. Recently, introduction of 
new oral P2Y
12
 inhibitors (prasugrel, ticagrelor), with a faster and more pronounced antiplatelet 
effect, have decreased the use of abciximab even in patients with STEMI. However, recent stud-
ies have shown a delayed onset of antiplatelet effect of new oral antiplatelet drugs in the setting 
of STEMI, especially in patients with hemodynamic compromise. Thus, the use of abciximab 
as an intravenous agent should be strongly considered when oral P2Y
12
 inhibitors might fail or 
cannot be given before primary PCI for STEMI. An additional benefit of abciximab administra-
tion was reported when abciximab was given early, before primary PCI, compared to typical 
periprocedural use. To the contrary, no clear clinical benefit was confirmed for intracoronary 
administration of abciximab compared with intravenous administration. Future studies should 
focus on the role of abciximab given on top of new oral P2Y
12
 inhibitor (prasugrel, ticagrelor) 
or used as an alternative to an intravenous P2Y
12
 inhibitor (cangrelor). Undoubtedly, the results 
of these studies will change everyday practice of STEMI treatment.
Keywords: glycoprotein IIb/IIIa inhibitors, acute myocardial infarction, percutaneous coronary 
intervention
Introduction
It is well recognized that platelets play a key role in the pathophysiology of acute 
coronary syndromes and thrombotic complications of percutaneous coronary inter-
vention (PCI). Introduction of antiplatelet agents, especially the glycoprotein (GP) 
IIb/IIIa receptor inhibitors, has contributed substantially to improving the outcome 
of patients with acute coronary syndromes. The prototypical agent abciximab is the 
Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab 
inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand 
factor, and other adhesive molecules to GP IIb/IIIa receptor sites on activated platelets. 
Antiplatelet effect of abciximab correlates with the degree of GP IIb/IIIa receptor 
blockade (maximal inhibition of platelets is achieved when $80% of GP IIb/IIIa recep-
tors are blocked). The maximal antiplatelet effect is usually present 10 minutes after 
bolus administration. Abciximab also binds to the vitronectin receptor (on platelets, 
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as well as endothelial and smooth muscle cells of the vessel 
wall) and to the activated Mac-1 receptor (on monocytes and 
neutrophils).1 The recommended dosage of abciximab is a 
0.25 mg/kg intravenous bolus followed by 12-hour infusion 
of 0.125 µg/kg/minute.
Abciximab – initial clinical 
experiences
Introduction of GP IIb/IIIa inhibitors has changed the daily 
practice of primary PCI for acute ST-segment elevation 
myocardial infarction (STEMI). Studies that assessed the 
value of abciximab during primary PCI for STEMI have 
shown benefits of such adjunctive pharmacotherapy, mainly 
driven by reduction of composite clinical end point (death, 
reinfarction, repeat revascularization).2–5 The largest benefit 
was seen in the reduction of need for urgent repeat revascular-
ization, but a higher risk of bleeding was observed in patients 
treated with abciximab. Importantly, the rate of bleeding was 
directly dependent on the administered dose of unfraction-
ated heparin. The significant increase in major bleeding was 
found in an abciximab group in the ReoPro and Primary 
PTCA Organization and Randomized Trial (RAPPORT) 
study with a dose of 100 U/kg of unfractionated heparin and 
recommended activated clotting time (ACT) .300 seconds.2 
In further trials, both the drug dose (usually 70 U/kg) and 
the recommended ACT (200–300 seconds) were reduced.3,4 
This influenced the bleeding rate and the significant differ-
ence in major bleeding was no longer present. In the largest 
meta-analysis of studies on abciximab in STEMI, including 
studies with both primary PCI and fibrinolysis, De Luca et al 
showed that abciximab administration was associated with 
a significant reduction in 30-day and long-term mortality in 
patients treated with primary PCI but not in those receiving 
fibrinolysis.6 The reinfarction at 30 days was reduced in 
the abciximab group in both primary PCI and fibrinolysis 
patients. Abciximab administration was associated with an 
increased risk of major bleeding when combined with fibrin-
olysis but not with primary PCI. Importantly, abciximab did 
not result in an increased risk of intracranial bleeding.6 The 
benefit from the routine administration of abciximab during 
primary PCI in patients with STEMI was confirmed mainly 
in studies with limited use of clopidogrel, especially given 
as a 600 mg loading dose.6
Most of the studies on the role of GP IIb/IIIa inhibitors in 
STEMI have focused on abciximab rather than on small-mol-
ecule GP IIb/IIIa inhibitors (eptifibatide, tirofiban). Despite 
the putative advantages of abciximab with respect to inhibi-
tion of additional proinflammatory pathways, small-molecule 
GP IIb/IIIa inhibitors appear to do as well as abciximab. Two 
meta-analyses7,8 showed similar results between high-dose 
tirofiban (25 µg/kg) (five trials) and eptifibatide (double 
bolus) (one trial) compared to abciximab among patients with 
STEMI undergoing primary PCI in terms of angiographic, 
electrocardiographic, and clinical outcomes. However, 
none of the trials were adequately powered to evaluate any 
difference in clinical end points, including mortality. The 
need for a second bolus (10 minutes after the first one) of 
eptifibatide may be less user-friendly in the setting of primary 
PCI. Contrarily to abciximab, dose adjustment is required 
for small-molecule GP IIb/IIIa inhibitors in patients with 
chronic kidney disease.9 On the other hand, compared with 
abciximab’s long clearance time of 12–24 hours, eptifibatide 
and tirofiban had a clearance time of only 2–2.5 hours, 
making them particularly attractive when urgent reversal 
of their effect was desirable.10 Based on American College 
of Cardiology Foundation/American Heart Association 
(ACCF/AHA)11 and European Society of Cardiology (ESC) 
STEMI9 guidelines, abciximab is recommended with level 
of evidence A, and eptifibatide (with double bolus) and 
tirofiban (with a high bolus dose) with level of evidence B. 
A lower level of evidence for small-molecule GP IIb/IIIa 
inhibitors is related to a limited amount of comparative data 
from placebo-controlled clinical trials.
Abciximab – current status
The use of a combination of unfractionated heparin and GP 
IIb/IIIa inhibitors in patients with STEMI has decreased over 
the last few years.12,13 Several factors are likely responsible 
for the decrease.
First, as the result of short- and long-term mortality 
benefit observed in patients treated with bivalirudin in the 
HORIZONS-AMI (heparin plus a glycoprotein IIb/IIIa 
inhibitor versus bivalirudin monotherapy and paclitaxel-
eluting stents versus bare-metal stents in acute myocardial 
infarction) study,14,15 the use of bivalirudin is preferred over 
combination of unfractionated heparin and GP IIb/IIIa inhibi-
tors in patients with STEMI, by current guidelines.9,11 Also, 
recently published results of the European Ambulance Acute 
Coronary Syndrome Angiography (EUROMAX) study16 have 
confirmed the safety and efficacy of bivalirudin administra-
tion during transfer for primary PCI. In this study, initiation 
of bivalirudin before transfer for primary PCI was associated 
with reduction of non-coronary artery bypass grafting-related 
major bleeding as well as a composite end point of death and 
non-coronary artery bypass grafting-related major bleed-
ing as compared to a control group at 30 days. However, in 
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HORIZONS-AMI and EUROMAX studies, the higher risk 
of stent thrombosis was observed in patients treated with 
bivalirudin,15,16 which may suggest the need for optimal anti-
platelet coverage during primary PCI for STEMI with more 
frequent use of GP IIb/IIIa inhibitors. Importantly, despite 
the inclusion of lower-risk patients, GP IIb/IIIa inhibitors 
were used in 7.2% of patients treated with bivalirudin in the 
HORIZONS-AMI study as a bailout.15
Second, the use of abciximab has waned due to the 
introduction of new P2Y
12
 inhibitors (prasugrel, ticagre-
lor) with a faster and more pronounced antiplatelet effect 
in  comparison to clopidogrel.17–20 Both prasugrel (TRial 
to Assess Improvement in Therapeutic Outcomes by 
Optimizing  Platelet InhibitioN with Prasugrel–Thrombol-
ysis In  Myocardial Infarction [TRITON-TIMI-38] study) 
and  ticagrelor (Platelet Inhibition and Patient Outcomes 
[PLATO] study) were shown to be more clinically effective 
than clopidogrel in terms of reduction of ischemic events 
in patients with acute coronary syndromes.21,22 Importantly, 
prasugrel significantly reduced the risk of cardiovascular 
events in patients with acute coronary syndromes undergo-
ing PCI regardless of whether or not a GP IIb/IIIa inhibitor 
was used. No impact of GP IIb/IIIa inhibitor on the relative 
risk of bleeding with prasugrel compared to clopidogrel was 
observed in the TRITON-TIMI-38 study;23 similarly, no inter-
action between effects of ticagrelor on ischemic and bleeding 
events and the use of GP IIb/IIIa inhibitors was confirmed in 
the PLATO study.22 However, in both studies, the impact of 
GP IIb/IIIa inhibitor (versus no GP IIb/IIIa inhibitor) used 
on top of these new oral drugs was not addressed.22,23 The use 
of prasugrel and ticagrelor is becoming more and more fre-
quent.24,25 Unfortunately, new P2Y
12
 inhibitors are often used 
as the replacement for intravenous GP IIb/IIIa inhibitors. Data 
from the FABOLUS PRO (Facilitation through Aggrastat By 
drOpping or shortening Infusion Line in patients with ST-
segment elevation myocardial infarction compared to or on 
top of PRasugrel given at loading dOse) study26 have shown 
a delayed onset of antiplatelet effect of new oral antiplatelet 
drugs in the setting of STEMI, and therefore have renewed 
the interest for GP IIb/IIIa inhibitors. The delayed onset of 
action of oral antiplatelet drugs may be expected, especially 
in patients with hemodynamic compromise,27 in cardiogenic 
shock,28 or after cardiac arrest in those undergoing mild 
induced therapeutic hypothermia.29,30 Similarly, gastroparesis 
may impair drug absorption in patients with diabetes mel-
litus.31 In such clinical scenarios, when acetylsalicylic acid 
and P2Y
12
 inhibitors might fail or cannot be given before pri-
mary PCI for STEMI, the use of abciximab as an intravenous 
agent should be strongly considered. Finally, some operators 
believe that mechanical reduction of thrombus burden during 
primary PCI with aspiration catheters may eliminate the need 
for the administration of GP IIb/IIIa inhibitors (mechanical 
instead of pharmacological approach). Pooled analysis of 
individual data of 2,686 patients enrolled in eleven random-
ized trials on the use of thrombectomy during primary PCI 
for STEMI clearly showed the highest mortality benefit when 
the use of thrombectomy was combined with administration 
of GP IIb/IIIa inhibitors.32 Similarly, in the Intracoronary 
abciximab and aspiration thrombectomy in patients with large 
anterior myocardial infarction (INFUSE-AMI) trial,33 the 
highest reduction of the infarct size assessed by cardiac mag-
netic resonance at 30 days after first anterior wall STEMI was 
observed when local infusion of abciximab was combined 
with prior thrombus aspiration. These findings may suggest 
the need for integration of mechanical and pharmacologi-
cal strategies to enhance reperfusion and improve clinical 
outcomes in patients with STEMI.
Abciximab, as a potent antiplatelet agent, decreases the 
risk of ischemic events, but, on the other hand, may carry 
an increased risk of bleeding. In a meta-analysis by De Luca 
et al, abciximab was associated with an increased risk of 
major bleeding complications when combined with fibrin-
olysis (5.2% versus 3.1%, P,0.001) but not with primary 
PCI (4.7% versus 4.1%, P=0.36).6 Abciximab did not result 
in an increased risk of intracranial bleeding (0.61% versus 
0.62%, P=0.62). In a more recent meta-analysis of studies 
on GP IIb/IIIa inhibitors, administration during primary PCI 
was associated with higher risk of major bleeding compli-
cations (3.9% versus 2.6%, P=0.0005).34 To minimize the 
risk of bleeding with abciximab, it is important to use a 
reduced-dose, weight-adjusted heparin regimen under ACT 
guidance, a weight-adjusted abciximab bolus and infusion, 
careful vascular access site management, and discontinuation 
of heparin after PCI. Also, the risk of puncture site-related 
bleeding may be decreased by the use of a radial approach. 
In a sub-analysis of the Acute STEMI Treated With Primary 
Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH 
to Lower Ischemic and Bleeding Events (ATOLL) study on 
patients with STEMI undergoing primary PCI, the addition 
of GP IIb/IIIa inhibitors in patients treated with a radial 
approach was not associated with bleeding liability.35 The use 
of GP IIb/IIIa inhibitors with a radial approach was associated 
with safer outcomes than using GP IIb/IIIa inhibitors with a 
non-radial approach.35 Importantly, if performed by an expe-
rienced radial operator, a radial approach should be preferred 
over a femoral approach in patients with STEMI.9
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Patients treated with abciximab are also at higher risk 
of thrombocytopenia (incidence of severe thrombocy-
topenia [platelet ,50,000 cells/µL] ranged from 0.4% to 
1%).36,37 Importantly, the risk of thrombocytopenia may 
be especially elevated in patients receiving abciximab 
re-administration.
Based on ACCF/AHA guidelines for the management of 
STEMI, abciximab in conjunction with unfractionated hepa-
rin or bivalirudin should be considered in selected patients 
(class IIa, level of evidence A).11 According to ESC STEMI 
guidelines, GP IIb/IIIa inhibitors should be considered for 
bailout therapy if there is angiographic evidence of massive 
thrombus, slow or no reflow, or a thrombotic complication 
(class IIa, level of evidence C).9 Routine use of a GP IIb/IIIa 
inhibitor as an adjunct to primary PCI performed with 
unfractionated heparin may be considered in patients without 
contraindications (class IIb, level of evidence B).9
Other abciximab  
administration strategies
Based on classic studies, abciximab is typically given as 
intravenous bolus during the PCI procedure, followed by 
intravenous infusion. However, different approaches, includ-
ing bolus-only (versus bolus plus infusion), early (versus 
periprocedural), or intracoronary (versus intravenous) admin-
istration are a matter of debate.
Bolus-only abciximab administration
Recommendations for intravenous bolus and infusion admin-
istration of abciximab is based on the The Evaluation of 7E3 
for the Prevention of Ischaemic Complications (EPIC) study, 
which showed superiority of bolus abciximab plus infusion 
compared with bolus alone.36 However, a recent study showed 
that withholding abciximab maintenance infusion does not 
impair platelet inhibition in patients receiving a 600 mg loading 
dose of clopidogrel.38 Similarly, Christ et al have shown that 
intracoronary abciximab bolus-only administration with oral 
P2Y
12
 inhibitor (600 mg of clopidogrel or 60 mg of prasugrel) 
initiation effectively inhibited overall platelet reactivity for at 
least 48 hours, which brings the value of continuous abcix-
imab infusion into question.39 The bolus-only strategy has the 
potential to improve the safety profile of abciximab (lower 
risk of bleeding) at reduced costs; however, there is no study 
confirming the clinical benefits of a bolus-only strategy.
early abciximab administration
Since primary PCI is the preferable method of reperfusion, 
it is very important to provide such treatment to as many 
patients with STEMI as possible. However, patient transfer 
to a primary PCI center can cause logistical problems that 
result in treatment delay. In recent years, efforts have been 
made to overcome this limitation with logistics improve-
ments and additional pharmacological strategies. After 
ADMIRAL (Abciximab before Direct angioplasty and stent-
ing in  Myocardial Infarction Regarding Acute and Long-term 
follow-up) trial results,3 attention was focused on the optimal 
time of abciximab administration. In this study, clinical 
 benefit of abciximab over placebo at 30 days and 6 months 
was especially pronounced in patients receiving abciximab 
before transfer to a primary PCI center. Importantly, in mul-
tivariable analysis, early abciximab administration was found 
to be a predictor of better outcome. However, this study was 
not focused on the role of early abciximab administration 
(only 26% of patients were randomized before transfer to a 
primary PCI center) and this was just post hoc observation.3 
Based on first, nonrandomized studies on early abciximab 
administration, it was suggested that early abciximab admin-
istration may increase the rate of patent infarct-related artery 
(IRA) before intervention and may be beneficial for outcome. 
In the Glycoprotein Receptor Antagonist Patency Evaluation 
(GRAPE) and ReoPro in acute MI (ReoMI) studies, patent 
IRA on baseline angiography was observed in 40%–50% of 
patients treated with early abciximab.40,41
After initial experiences, a large number of randomized 
studies comparing early and late (during PCI) abciximab 
administration were performed.42–53 Most of these were 
powered for surrogate end points, ie, IRA patency before 
angiography and myocardial reperfusion parameters before 
and after PCI (electrocardiographic ST-segment elevation 
resolution, angiographic myocardial blush grade).42–50 Most 
of the studies showed that early abciximab administration is 
associated with a higher rate of early IRA patency and better 
myocardial reperfusion parameters before and after PCI,42–46 
but some showed a benefit only before PCI47,48 or even no ben-
eficial effect of early abciximab administration (minority).49,50 
In some studies, infarct size and left ventricular function 
were assessed, showing, for the most part, beneficial effects 
of early abciximab administration on those parameters,44,51,52 
but negative results53 were also reported.
The abovementioned studies,42–50 were underpowered 
to assess clinical end points; hence, much attention was 
focused on the Facilitated Intervention with Enhanced Rep-
erfusion Speed to Stop Events (FINESSE) trial,54 which was 
a double-blind, placebo-controlled study, with randomiza-
tion to combination-facilitated PCI (reteplase, abciximab), 
abciximab-facilitated PCI, or primary PCI. However, enroll-
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ment in the FINESSE trial was slow (from 2002 to 2006), 
and was stopped before the planned enrollment of 3,000 
patients had been achieved. Additionally, a substantial pro-
portion of patients were enrolled once in a PCI center, rather 
than before transfer. The FINESSE trial showed no clinical 
benefit of early abciximab administration, despite a higher 
rate of early IRA patency as compared to late abciximab 
administration.54 However, in the sub-analysis of FINESSE 
results, Herrmann et al showed improved survival at 1 year 
after facilitation of PCI in high-risk patients presenting to a 
spoke hospital within 4 hours of symptom onset (symptom- 
to-randomization time).55 In the meantime, based on previously 
described smaller studies, early abciximab administration 
before transfer to a catheter laboratory was introduced as 
routine therapy in various European STEMI networks. Based 
on experiences of those European STEMI networks, the idea 
of registry introduction was born. The European Registry 
on Patients With ST-Elevation MI Transferred for Mechani-
cal Reperfusion (PCI), With a Special Focus on Upstream 
Use of Abciximab (EUROTRANSFER) Registry56 was a 
European, prospective, multicenter observational study 
including patients transferred (from a referral hospital or by 
pick-up from an ambulance) to a primary PCI center. The 
study was focused on the timing of abciximab application 
and related clinical outcomes. Early abciximab administra-
tion was associated with lower 30-day mortality and 30-day 
composite clinical end point compared to periprocedural 
abciximab administration. The difference was significant 
in favor of early abciximab, including after adjustment 
with multivariate regression and propensity score.56 In the 
additional analysis, based on patient risk profiles, the benefit 
of early abciximab administration was most pronounced in 
high-risk patients ($3 points in TIMI Risk Score).57 Clini-
cal outcome was also assessed in post hoc analysis of the 
Assessment of Pexelizumab in Acute Myocardial Infarction 
(APEX-AMI) trial, showing that pharmacological pretreat-
ment with GP IIb/IIIa inhibitors (particularly with abciximab) 
was associated with a lower rate of 90-day clinical events.58 
The strategy of early abciximab administration was shown 
to be superior over periprocedural administration in various 
subgroups of STEMI patients, including elderly and diabetic 
patients.59,60
The role of early GP IIb/IIIa administration was also 
assessed in several meta-analyses, two of which showed 
benefits from early pretreatment strategy assessed with 
surrogate, but not clinical, end points.61,62 Finally, the Early 
Glycoprotein IIb/IIIa Inhibitors in Primary  Angioplasty 
(EGYPT) individual patient data meta- analysis (1,662 patients) 
was performed and showed that early  administration of 
GP IIb/IIIa inhibitors before primary PCI for STEMI is 
associated with better preprocedural epicardial recanalization 
and ST-segment resolution after primary PCI. The nonsignifi-
cant reduction of mortality after early administration strategy 
was present in the whole population, but a significant mortal-
ity benefit was found when abciximab-treated patients were 
analyzed.63 Long-term results on early upstream administra-
tion of abciximab in STEMI patients were analyzed in the 
Early Glycoprotein IIb/IIIa Inhibitors in Primary Angioplasty-
Abciximab Long-Term Results (EGYPT-ALT) individual 
patient data meta-analysis and showed significant benefits in 
terms of pre- and postprocedural epicardial flow in IRA and 
postprocedural myocardial reperfusion (electrocardiographic 
ST-segment elevation resolution and angiographic myocardial 
blush grade), as well as mortality reduction at long-term 
follow-up (median of 1,095 days).64
In summary, in randomized studies, the strategy of early 
abciximab administration before angiography in patients with 
STEMI referred for primary PCI showed better results than 
periprocedural administration, but only on surrogate, and not 
on clinical, end points. Clinical benefit of early administration 
of abciximab (including mortality reduction) was confirmed 
by the EUROTRANSFER Registry results56 and meta-
analyses.61–64 Importantly, early abciximab administration 
does not increase rate of bleeding compared to in-cath-lab 
administration. Based on ESC STEMI guidelines, upstream 
use of a GP IIb/IIIa inhibitor (versus in-lab use) may be 
considered in high-risk patients undergoing transfer for pri-
mary PCI.9 However, this strategy is currently less popular in 
daily practice, mostly due to improvements in the logistics of 
STEMI treatment (delay reduction) and introduction of new 
oral antiplatelet drugs (prasugrel and ticagrelor). It should 
be underlined that studies on early abciximab administration 
were performed in the era of clopidogrel treatment and, in a 
large proportion of those trials, clopidogrel was given after 
admission to a catheter laboratory. There are no data on early 
abciximab administration in patients treated with prasugrel 
and ticagrelor.
intracoronary versus  
intravenous administration
In most cases, GP IIb/IIIa inhibitors, including abciximab, 
are used as intravenous bolus and infusion during primary 
PCI. On the other hand, during primary PCI, the intracoro-
nary administration of abciximab can be easily performed 
using a guiding catheter, which may result in a more pro-
nounced local inhibition of platelet function and a higher 
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degree of GP IIb/IIIa receptor occupancy when compared 
to standard intravenous bolus injection.65 Single cases of 
dethrombotic effect using an intracoronary bolus have been 
reported.66–68 Initial nonrandomized studies suggested greater 
benefit from selective intracoronary administration using a 
guiding catheter.69,70 Further, in a small randomized study, 
intra coronary administration of abciximab during primary 
PCI improved reperfusion parameters and reduced infarct 
size in comparison with intravenous use.71 In addition, 
a trend toward a lower major adverse cardiac event rate at 
30 days after intracoronary versus intravenous abciximab 
application was observed.71 To the contrary, the recently 
published randomized CICERO (Comparison of Intra-
Coronary versus intravenous abciximab administration 
during Emergency Reperfusion Of ST-segment elevation 
myocardial infarction) trial72 showed no benefit in terms of 
myocardial reperfusion and clinical outcome associated with 
intracoronary administration of abciximab in 534 patients 
with STEMI undergoing primary PCI. Additionally, the 
randomized Abciximab Intracoronary versus intravenously 
Drug Application in STEMI (AIDA STEMI) trial,73,74 includ-
ing more than 2,000 patients, did not prove any benefit in 
reduction of clinical end points relating to intracoronary 
over intravenous administration of abciximab during short- 
and long-term follow-up. None of the secondary end points 
(including early ST-segment resolution, thrombolysis in 
myocardial infarction flow grade, and enzymatic infarct size) 
or safety measures differed significantly between groups. 
A cardiac magnetic resonance substudy of the AIDA STEMI 
trial75 demonstrated no benefit of intracoronary versus intra-
venous abciximab administration on myocardial damage 
and/or reperfusion injury. In a meta-analysis of eight studies 
including 3,259 patients, intracoronary administration of 
abciximab was associated with a significant improvement 
in myocardial perfusion, without significant benefits in 
terms of mortality, reinfarction, or major bleeding compli-
cations.76 However, a significant relationship was observed 
between a patient’s risk profile and mortality benefits from 
intracoronary abciximab administration. Similarly, in a more 
recent pooled analysis of individual patient data from five 
randomized controlled trials (3,158 patients with STEMI), 
intracoronary abciximab administration was not associated 
with additional benefits compared with standard intravenous 
treatment.77
Another administration option is intralesional infusion of 
abciximab using a dedicated therapeutic perfusion catheter.78 
Local administration of abciximab may increase concentra-
tions at the culprit lesion and in the distal vascular bed, as 
well as allow for optimization of the diffusion of abciximab 
to platelets within flow-limiting thrombi. Further, the non-GP 
IIb/IIIa properties of abciximab mediated through inhibition 
of the vibronectin and Mac-1 receptors may be greater at 
higher local concentrations.79 By potentiating the local 
anti-inflammatory effects of abciximab, reperfusion injury 
may be minimized, resulting in greater myocardial salvage. 
Data from the randomized ClearwayRx System to reduce 
intracoronary thrombus in patients with acute coronary 
syndromes according to Optical Coherence Tomography 
after Abciximab Intracoronary Local infusion (COCTAIL) 
study80 have shown that administration of abciximab by local 
intracoronary infusion through the ClearWay™ RX (Atrium 
Medical Corporation, Hudson, NH, USA) catheter can reduce 
thrombus burden and improve coronary microcirculation. In 
the randomized INFUSE-AMI trial,33 local administration of 
abciximab with the ClearWay™ RX catheter was associated 
with significant, albeit modest, reduction of the infarct size 
assessed by cardiac magnetic resonance at 30 days after 
first anterior wall STEMI in comparison to no abciximab 
administration. The highest benefit was observed when local 
infusion of abciximab was combined with prior thrombus 
aspiration. At 12 months, there was no difference in mortal-
ity, composite ischemic events, or heart failure-related events 
between patients treated with intralesion administration of 
abciximab and those without abciximab.81
Despite no clear clinical benefit from routine use of 
intracoronary or intralesional administration of abciximab, 
both constitute safe approaches for drug administration, 
although local delivery should generally be preferred over 
guide-catheter infusion to limit drug administration to 
non-culprit coronary arterial branches. Based on ACCF/
AHA guidelines for the management of STEMI, it may 
be reasonable to administer intracoronary abciximab to 
patients with STEMI undergoing primary PCI (class IIb, 
level of evidence B).11 Based on ESC STEMI guidelines, the 
intracoronary route may be considered, but the intravenous 
route should remain the standard of care for administration 
of GP IIb/IIIa inhibitors.9
Future perspectives  
and ongoing studies
Future studies will likely focus on the role of GP IIb/IIIa 
inhibitors in patients with STEMI pretreated with new 
oral P2Y
12
 inhibitors. Given the limitations for immediate 
action of oral antiplatelet agents, a new intravenous P2Y 
12
 
inhibitor – cangrelor – was introduced. In a meta-analysis 
of three randomized studies, cangrelor was shown to reduce 
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periprocedural thrombotic complications of PCI as compared 
with control (clopidogrel or placebo).82 Despite excellent 
results with new oral P2Y
12
 inhibitors, we can expect some 
head-to-head comparisons between abciximab and cangrelor 
in the near future. Further, the optimal technique for abcix-
imab administration is still under investigation. For example, 
the COCTAIL II study83 aims to demonstrate that abciximab 
infusion with the ClearWay™ RX catheter, with or without 
manual thrombus aspiration, will result in a significant 
reduction of intra-stent thrombus formations when compared 
with intravenous or intracoronary abciximab with or without 
thrombectomy. Additionally, the Thrombus aspiration for 
OccLuded coronary artery Enhanced with Distal injection Of 
abciximab (TOLEDO1) study (ClinicalTrials.gov identifier: 
NCT01383785) will assess the impact of distal injection 
of abciximab using a manual aspiration catheter after ini-
tial thrombus aspiration during primary PCI for STEMI. 
Future studies should also reevaluate the role of abciximab 
in patients treated with new stent designs (ie, mesh-covered 
stents, self-expandable stents) that are dedicated to lesions 
with a large thrombus burden.84,85
Conclusion
Currently, management of patients with STEMI involves not 
only mechanical restoration of the flow within the IRA, but also a 
system of early diagnosis and rapid transfer to PCI-capable cen-
ters; selection of optimal adjunctive pharmacotherapy (including 
timing and model of abciximab administration); and, finally, 
PCI procedure with dedicated devices. Abciximab may reduce 
the rate of clinical events, including mortality, in patients with 
STEMI, especially in high-risk patients. Thus, current guidelines 
recommend the selective use of abciximab for patients with 
a high risk of ischemic events (large anterior wall infarction, 
large thrombus burden) and/or angiographic complications 
(distal embolization, no reflow phenomenon) of primary PCI, 
especially in patients with a low risk of bleeding. Abciximab 
may also be considered in patients with expected delayed onset 
of action of oral antiplatelet drugs (patients with hemodynamic 
compromise, cardiogenic shock, cardiac arrest undergoing mild 
induced therapeutic hypothermia). On the other hand, the role of 
abciximab in patients with STEMI pretreated with new P2Y
12
 
inhibitors, which are becoming more and more popular, is not 
yet properly defined. The intracoronary route of administration 
of abciximab may be reasonable, with possible intralesional 
application in patients with a very large thrombus load at the 
site of IRA occlusion. To improve safety of the administration 
of abciximab, the use of a radial approach should be strongly 
considered in patients undergoing primary PCI.
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